A. Kauppi

发表

Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides.

C. D. Andersson, A. Linusson, M. Elofsson, 2007, Bioorganic & medicinal chemistry.

Phospholipid levels in blood during community-acquired pneumonia

A. Sjöstedt, A. Johansson, Å. Gylfe, 2019, PloS one.

Design, synthesis, and multivariate quantitative structure-activity relationship of salicylanilides--potent inhibitors of type III secretion in Yersinia.

Markus K. Dahlgren, A. Linusson, M. Dahlgren, 2007, Journal of medicinal chemistry.

Efficient Solution‐Phase Parallel Synthesis of 4‐Substituted N‐Protected Piperidines

R. Olsson, F. Almqvist, Xiaoyang Wang, 2003 .

CHEMICAL ATTENUATION OF BACTERIAL VIRULENCE: SMALL MOLECULE INHIBITORS OF TYPE III SECRETION

A. Kauppi, 2006 .

Small-Molecule Inhibitors Specifically Targeting Type III Secretion

H. Wolf‐Watz, M. Elofsson, R. Nordfelth, 2005, Infection and Immunity.

Targeting bacterial virulence: inhibitors of type III secretion in Yersinia.

Hans Wolf-Watz, Mikael Elofsson, H. Wolf‐Watz, 2003, Chemistry & biology.

Metabolites in Blood for Prediction of Bacteremic Sepsis in the Emergency Room

A. Sjöstedt, A. Johansson, Å. Gylfe, 2016, PloS one.

High prevalence of persistent symptoms and reduced health-related quality of life 6 months after COVID-19

C. Ahlm, J. Sundh, J. Normark, 2023, Frontiers in Public Health.

Salicylanilides are potent inhibitors of type III secretion in Yersinia.

H. Wolf‐Watz, M. Elofsson, R. Nordfelth, 2003, Advances in experimental medicine and biology.

Metabolites in Blood for Prediction of Bacteremic Sepsis in the Emergency Room

A. Sjöstedt, A. Johansson, Å. Gylfe, 2016, PloS one.